ApconiX is supporting PhysioStim at SPS

ApconiX and PhysioStim will be celebrating their first year of The European Centre of Excellence for preclinical cardiovascular electrophysiology at the Safety Pharmacology Society Annual Meeting in Washington this September.  ApconiX will be supporting PhysioStim as they exhibit at the Marriott Wardman Park Hotel on Stand 412 from the 30th of September to the 3rd October.

Come and say “hello” to Marie Le Grand, Richard Printemps and Mike Morton who will be very happy to answer your questions on preclinical cardiac safety studies, both in the GLP and non-GLP format.

In combining both company’s extensive expertise, The Centre offers a complete range of studies from screening to customised problem-solving. The service includes automated electrophysiology providing hERG screening and CiPA ion channel assays, GLP compliant assays: manual patch-clamp assays (hERG, hNav1.5, hCav1.2), action potential recordings, Langendorff models and cardiac contractility studies.

The Centre is designed to help companies make better decisions in selecting the optimal clinical lead candidates at an early stage.  Additional to the ion channel screening and assay development, ApconiX provides expert nonclinical safety expertise to help put this data into context for each drug project.

From target review to regulatory approval, ApconiX helps organisations to assess, reduce and manage potential risk factors and bring safe, effective and profitable drugs to market.

Look forward to seeing you in Washington!

By |2018-09-25T18:23:43+00:00September 26th, 2018|Ion Channels, Events|Comments Off on ApconiX is supporting PhysioStim at SPS

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.